EGFR and lip and oral cavity carcinoma: Moreover, two randomized trials (SPECTRUM and ZALUTE) which evaluated different anti-EGFR monoclonal antibodies (panitumumab and zalutumumab, respectively) also showed preferential antitumor effects compared with their control arms in patients with primary oral cancer (PFS-HRs: 0.70 [95%CI: 0.51-0.96] and 0.54 [0.31-0.93], respectively) (31–33).